MARKET

CHRS

CHRS

Coherus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.39
-0.17
-0.97%
After Hours: 17.39 0 0.00% 16:00 09/20 EDT
OPEN
17.05
PREV CLOSE
17.56
HIGH
17.70
LOW
16.96
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
22.22
52 WEEK LOW
12.21
MARKET CAP
1.33B
P/E (TTM)
-7.5161
1D
5D
1M
3M
1Y
5Y
Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced interim results from the Phase 3 JUPITER-06 trial.
Benzinga · 3d ago
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – - Coherus and Junshi Biosciences plan ...
GlobeNewswire · 4d ago
Coherus, Junshi Biosciences Announce Results From Phase 3 Study Of Toripalimab Published In September Issue Of Nature Medicine
Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) and Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) today announced publication of a cover article in the
Benzinga · 5d ago
BRIEF-Junshi Biosciences, Coherus Report Results from Study of Toripalimab Published in September Issue of Nature Medicine
reuters.com · 5d ago
Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
- Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma -REDWOOD CITY, Calif., and SHANGHAI, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and ...
GlobeNewswire · 5d ago
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 6d ago
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
SHANGHAI, China and REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Nasdaq: CHRS) announced the presentation today of positive int...
GlobeNewswire · 09/14 00:55
BRIEF-Coherus Biosciences And Shanghai Junshi Biosciences Announced Presentation Of Positive Interim Results From Pivotal Study "Choice-01"
reuters.com · 09/14 00:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CHRS. Analyze the recent business situations of Coherus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CHRS stock price target is 25.71 with a high estimate of 36.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 285
Institutional Holdings: 89.80M
% Owned: 117.42%
Shares Outstanding: 76.48M
TypeInstitutionsShares
Increased
81
5.02M
New
21
634.08K
Decreased
57
4.15M
Sold Out
37
3.84M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dennis Lanfear
Chief Financial Officer
McDavid Stilwell
Chief Operating Officer
Vincent Anicetti
Chief Scientific Officer
Vladimir Vexler
Other
Thomas Fitzpatrick
Lead Director/Independent Director
Mats Wahlstrom
Director
Alan Mendelson
Independent Director
James Healy
Independent Director
Samuel Nussbaum
Independent Director
Ali Satvat
Independent Director
Mark Stolper
Independent Director
Kimberly Tzoumakas
No Data
  • All
  • Financials
  • Insiders
More
About CHRS
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Webull offers kinds of Coherus Biosciences Inc stock information, including NASDAQ:CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.